The real-time intraoperative guidance of the new HIFU Focal-One® platform allows to minimize the perioperative adverse events in salvage setting

Purpose To assess the use of the new Focal-One ® HIFU platform in salvage setting to evaluate the occurrence of postoperative complications. Methods Patients who underwent salvage HIFU (sHIFU) with Focal-One ® platform were enrolled prospectively (Candiolo cancer institute—FPO IRCCS; registry number...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of ultrasound 2022-06, Vol.25 (2), p.225-232
Hauptverfasser: Checcucci, Enrico, De Luca, Stefano, Piramide, Federico, Garrou, Diletta, Mosca, Alessandra, Galla, Andrea, Belli, Gaetano, Russo, Filippo, Rescigno, Pasquale, Poti, Carlo, Amparore, Daniele, Verri, Paolo, Volpi, Gabriele, Manfredi, Matteo, Fiori, Cristian, Porpiglia, Francesco
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Purpose To assess the use of the new Focal-One ® HIFU platform in salvage setting to evaluate the occurrence of postoperative complications. Methods Patients who underwent salvage HIFU (sHIFU) with Focal-One ® platform were enrolled prospectively (Candiolo cancer institute—FPO IRCCS; registry number: 258/2018). Perioperative and postoperative outcomes (in terms of oncological and functional ones) were recorded during the first year of follow-up. In particular postoperative complications were classified according to Clavien–Dindo system. Results 20 patients were enrolled. No grade 3 complications were recorded. Referring to grade 2 complications, eight patients reported urgency after 3 months of follow-up, and in 4 cases, a low urinary tract infection occurred. Evaluating the impact of sHIFU on patients’ sexual potency, micturition and quality of life, no significant deterioration was recorded during the follow-up as proven using the ANOVA analysis for repeated measurements. Only two patient had a biochemical failure after 12 months of follow-up. Conclusions The real-time intraoperative guidance with Focal-One ® platform, allows a continuous monitoring and tailoring of the treatment, with a minimization of the adverse events even in a salvage setting.
ISSN:1876-7931
1971-3495
1876-7931
DOI:10.1007/s40477-021-00594-8